Thus, hypertriglyceridemia represents a target for further intervention. Clinical trials have shown that high-dose eicosapentaenoic acid (EPA) is effective in reducing the risk of atherosclerotic cardiovascular disease (ASCVD) in patients receiving statins, and it is currently being incorporated into combination lipid-modifying therapy strategies for the aggressive treatment of patients at highest risk. This review summarizes the concepts underlying the use of high-dose EPA alongside intensive LDL-lowering therapy, particularly in the context of post-acute coronary syndrome. A practical implementation algorithm is presented, outlining combination therapy treatment options and the role of high-dose EPA in ASCVD prevention in patients with hypertriglyceridemia.